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Outcomes in RCT's of antipsychotic medications are often examined using last observation
carried forward (LOCF) and mixed effect models (MMRM), these ignore meaning of non-
completion and thus rely on questionable assumptions. We tested an approach that combines
into a single statistic, the drug effect in those who complete trial and proportion of patients in
each treatment group who complete trial. This approach offers a conceptually and clinically
meaningful endpoint. Composite approach was compared to LOCF (ANCOVA) and MMRM in 59
industry sponsored RCT's. For within study comparisons we computed effect size (z-score) and p
values for (a) rates of completion, (b) symptom change for complete cases, which were
combined into composite statistic, and (c) symptom change for all cases using last observation
forward (LOCF). In the 30 active comparator studies, composite approach detected larger
differences in effect size than LOCF (ES=.05) and MMRM (ES=.076). In 10 of the 49 comparisons
composite lead to signiﬁcant differences (pr.05) where LOCF and MMRM did not. In
3 comparisons LOCF was signiﬁcant, in 2 MMRM lead to signiﬁcant differences whereas
composite did not. In placebo controlled trials, there was no meaningful difference in effectCNP.
o.2013.11.010
4 464 3889.
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J. Rabinowitz et al.358size between composite and LOCF and MMRM when comparing placebo to active treatment,
however composite detected greater differences than other approaches when comparing
between active treatments. Composite was more sensitive to effects of experimental
treatment vs. active controls (but not placebo) than LOCF and MMRM thereby increasing study
power while answering a more relevant question.
& 2013 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Dropout or discontinuation is a major cause of missing data in
clinical trials generally, and trials of antipsychotic medica-
tions, in particular. It is an important outcome as it may
reﬂect a lack of drug tolerability, lack of efﬁcacy, adverse
effects or lack of compliance. It creates uncertainty in
interpreting study results. It is not uncommon for dropout
rates of antipsychotic medication trials to exceed 50% (Martin
et al., 2006; Rabinowitz et al., 2009; Wahlbeck et al., 2001).
In our NewMeds repository completion rate in the 30 active
controlled studies (n=12,846, treatment duration 4–104
weeks) was only 48.7% and in the 29 placebo controlled trials
(n=9174, treatment duration 4–52 weeks) the completion rate
was only 53.9% (after removing two trials longer than 8 weeks
for comparability). Recently, there has been increased recog-
nition of the problem of missing data in clinical trials by
regulatory authorities (O'Neill and Temple, 2012) and the
limitations of conventional ways of accounting for it.
Dropout leads to missing data that varies as to the extent to
which it affects modeling and analysis. The literature distin-
guishes between three mechanisms of missing data (Little and
Rubin, 1987). First, missing completely at random (MCAR); this
refers to a situation where missingness does not depend on
either the observed or unobserved data. A possible example is
data lost because some patient records were destroyed in a
ﬂood. MCAR can be handled in the analysis using standard
approaches such as mixed models or LOCF. Nevertheless MCAR
leads to loss of power due to diminished sample size. Second,
missing at random (MAR) occurs if the missing data depends
on variables that are observed during the trial and not on
unobserved data. The data is MCAR if, for example, the
probability of dropout is unrelated to any of the other variables
of potential interest and relevance (e.g. the rate of dropout is
unrelated to starting severity, illness type, age, gender etc.). If
the probability of dropout varies by a given variable, say gender
of the subject, but since gender is known one can examine the
differences within a gender and hence control for it. If after
controlling for gender (i.e. within men and women separately)
the dropouts are unrelated to any further variable the data are
MAR. Third, missing not at random (MNAR) occurs if the
missingness depends on unobserved data. An example could
be a patient who was improving and then was lost to follow-up
because of a relapse after the last observed visit and was
admitted to a different hospital. In this case the observed data
could not predict the missing data. The unobserved data
contained information not foreseen by the observed data
(Mallinckrodt et al., 2003). MNAR cannot be corrected without
explicitly specifying a model for the missing data mechanism,
which by deﬁnition, cannot be tested.
MCAR and MAR are termed ignorable non-response since
the ﬁrst requires no special attention when analyzing thedata and the second can be controlled for in the analysis.
MNAR is termed non-ignorable non-response since it cannot
be ignored. It cannot be ignored as it is informative, for
example dropout due to lack of efﬁcacy. In-fact MAR and
MNAR are also sometimes referred to as “informative” as
the data that is missing is informative as it relates to study
variables.
Missing data in clinical trials of antipsychotic medication
because of dropout are problematic since they are rarely
MCAR and it is generally difﬁcult to determine if they are MAR
or MNAR. Historically, a standard approach used in clinical
trials is the last observation carried forward (LOCF). LOCF uses
the last completed observation while on treatment to esti-
mate a hypothetical last visit value. This is problematic since
it assumes that the data are MCAR and that symptoms would
have remained stable and constant, with no within-subject
variation after dropout. This leads to inﬂation of Type I error
rates, since the estimated standard error of test statistics is
biased downward until the end of the trial. Some recent trials
(Duan et al., 2006; Lieberman et al., 2005; Lieberman et al.,
2003) have applied a mixed-effects model (Mallinckrodt et al.,
2003) which is thought to provide more accurate estimates of
treatment than LOCF. LOCF analysis can lead to substantial
biases in estimating treatment effects and can greatly inﬂate
Type I error rates of the statistical tests, whereas MMRM
analysis on the available data leads to estimates with smaller
bias, and controls Type I error rates at a nominal level in the
presence of missing completely at random (MCAR) or missing
at random (MAR) (Siddiqui et al., 2009). These estimates are
based on data available at each given time point. Mixed-effect
models work if data is MCAR or MAR, however if the data is
MNAR then inferences based on these methods will probably
not be valid.
The above highlights that when using standard approaches,
the mechanism of dealing with missing data is of critical
importance. However, an alternative and newer approach
has been proposed to address the dropout problem (Shih and
Quan, 1997) which can be applied regardless of the missing
data mechanism. This approach termed the composite
approach was developed by Shih and Quan (Shih and Quan,
1997). It combines two hypotheses stating that more patients
will complete the trial on the better drug and that patients
who complete the trial will improve more on the better drug.
Accordingly, this is termed the composite approach. Speciﬁ-
cally, this approach (Shih and Quan, 1997) combines the p
value of the difference in completion rates between drug
treatments and the p value obtained in comparing the
difference in treatment outcomes of complete cases. The
approach gives a single p value that reﬂects both outcomes. If
the result is statistically signiﬁcant it means that the groups
differ on the combined hypothesis. Thus when the null
hypothesis is rejected, the conclusion is that the chance of
359Combining efﬁcacy and completion rates with no data imputationcompleting the trial and/or the treatment effect given
completing the trial is superior.
The composite approach provides a statistically more
powerful test than testing both measures separately. Also,
conceptually, it is more meaningful to examine these two
outcomes together since symptom improvement without
study completion is generally not a favorable outcome. In a
previous paper (Rabinowitz and Davidov, 2008) we illu-
strated the use of this approach using data from 11 trials
reporting sufﬁcient data in the literature to apply this
approach. The results of that pilot study were encouraging
regarding the possibility that the composite approach would
increase statistical power by increasing effect sizes. Com-
posite results were statistically signiﬁcant in two trials
where LOCF was not.
In the current analysis we have applied the composite
approach to the largest repository of antipsychotic drug trials,
the NewMeds Repository which includes 29 placebo-controlled
and 30 active treatment controlled randomized trials of
second generation antipsychotic medications for the treat-
ment of schizophrenia. We compared the composite approachTable 1 Effect size d (z-scores) for completion (yes/no), chan
Comparisons
between arms
Yes/no
completion
Completers
change
from
baseline
ANCOVA
Composite (s
of previous
columns/sqr
Active treatment
comparator studies
(k=30)
Comparisons between
arms (n=70)
Study drug vs. control
(n=49)
.15 .12 .19
Study drug vs. FGA
control (n=21)
.06 .14 .15
Study drug vs. SGA
control (n=28)
.21 .10 .22
Comparison of same
active drug different
dose arms (n=21)
.03 .03 .003
Placebo treatment
comparator studies
(k=29)
Placebo vs. study drug
arms (n=73)
.24 .24 .34
SGA vs. FGA control
(n=31)
.07 .02 .06
Same active drug
different dose arms
(n=61)
.09 .08 .12
SGA vs. control SGA
(n=9)
.01 .04 .03
Placebo vs. FGA
(n=10)
.13 .19 .22
a(mean1+mean2)/square root of 2 (Mosteller and Bush, 1954).to LOCF (ANCOVA) and also to multivariate or mixed model for
repeated measurements (MMRM). We have also expanded the
composite approach, which was previously used to test
the null hypotheses, by combining p values to also examine
the magnitude of effects by combining effect sizes which were
computed for each test.2. Experimental procedures
The NEWMEDS repository includes anonymized patient data from
AstraZeneca, Janssen, Eli Lilly, Lundbeck, and Pﬁzer from 29
placebo-controlled trials of second-generation antipsychotics (pla-
cebo, n=2200; active treatment, n=6971) in schizophrenia, all of
which demonstrated at least one active treatment arm to be
superior to placebo, and 30 active comparator studies
(n=12,846). An overview of studies is presented in Online
Supplement 1. To examine how the composite approach would
affect trial outcome we applied it to all of these industry sponsored
RCT's in our NewMeds repository of second generation antipsychotic
trials. Composite approach was compared to LOCF (ANCOVA) and to
multivariate or mixed model for repeated measurements (MMRM).ge from baseline for completers.
um
2)a
LOCF change
from baseline
ANCOVA
Mixed
models
Difference
between
composite d
and LOCF d
Difference
between
composite d and
mixed models d
.14 .11 ES=.05 ES=.08
.06 .07 ES=.09 ES=.13
.20 .19 ES=.02 ES=.04
.067 .05 ES=.07 ES=.05
.35 .38 ES=.01 ES=.04
.04 .004 ES=.10 ES=.06
.08 .11 ES=.04 ES=.01
1.02 .02 ES=.02 ES=.01
.45 .42 ES=.23 ES=.20
Table 2 Comparing composite p value with LOCF (ANCOVA) and Mixed Effects Models.
Comparisons between arms LOCF MMRM
Composite
p value lower
than LOCF
Composite
approach
signiﬁcant
LOCF not
LOCF (ANCOVA)
signiﬁcant
Composite
not
Both
signiﬁcant
Neither
signiﬁcant
Composite
p value lower
than Mixed
Composite
approach
signiﬁcant
Mixed not
Mixed
signiﬁcant
Composite
not
Both
signiﬁcant
Neither
signiﬁcant
Active treatment comparator
studies (k=30)
Study drug vs. control (n=49) 65.3%
(n=32/49)
10 3 7 29 89.8%
(n=44/49)
10 2 7 30
Study drug vs. FGA control (n=21) 71.4%
(n=15/21)
3 1 2 15 95.2%
(n=20/21)
4 0 1 16
Study drug vs. SGA control (n=28) 60.7%
(n=17/28)
7 2 5 14 85.7%
(n=24/28)
6 2 6 14
Comparison of same active drug
different dose arms (n=21)
52.4%
(n=11/21)
0 1 2 18 85.7%
(n=18/21)
0 2 2 17
Placebo treatment comparator
studies (k=29)
Placebo vs. study drug arms (n=73)a 24.7%
(n=18/73)
4 8 40 21 43.8%
(n=32)
12 8 32 21
Comparison of same active drug
different dose arms (n=61)
40.0%
(n=24/60)
6 5 4 45 33.3%
(n=20)
7 6 3 44
Comparison of control SGA and
study drug SGA (n=9)
55.6%
(n=5/9)
2 0 0 7 55.6%
(n=5)
2 0 0 7
Placebo vs. FGA (n=10) 0 0 7 3 0 1 0 4 3 3
aTwo studies failed to show placebo active treatment superiority in all arms based on LOCF but succeeded on composite. No studies showing signiﬁcant difference on LOCF would have
completely failed to show active treatment placebo superiority based on composite, at least one arm was signiﬁcant.
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For all possible comparisons between arms within each study, we
computed an effect size (z-score) and p value for completion (yes/no,
Chi-square), and change from baseline to endpoint on the PANSS
(ANCOVA with adjustment for baseline) for all patients and for
completers. MMRM was run to estimate the endpoint effects. Fixed
effects in the model were treatment, site, week, treatment-by-week
interaction and baseline score-by-week interaction. The adjustment
for random subject variation is incorporated in the covariance
structure which is chosen to be completely unstructured.
Both composite p and effect size scores were computed by
combining the respective p and z-scores for completion (yes/no)
and change from baseline. Using standard approaches composite
z-scores were computed by adding z-scores (and dividing by square
root of 2) (Mosteller and Bush, 1954), and composite p values using
adding the log of p values as per Shih and Quan (Shih and Quan,
1997). Using their approach p-values were combined as follows:
p=p(d)p(e) (1 ln(p(d)p(e)), where p(d) is the p value of
difference in dropout and p(e) is the p value of difference in
completers analysis of efﬁcacy. Thus if one p value is .08 and the
second is .10, the combined p value is .047 (.08 .10 (1(ln
(.08 .10)))). In keeping with Shih and Quan (Shih and Quan, 1997),
p values could not logically be combined if the efﬁcacy and
completion effects were not in the same direction (e.g., drop outTable 3 Active treatment studies where LOCF and Composite
Study Comparisons of study drug and active comparator arms C
p
Comparisons (n=4) where LOCF is signiﬁcant and Composite is n
1 Study drug becomes non-signiﬁcant .
2 High low dose study drug no longer signiﬁcant .
3 Study drug no longer signiﬁcant since completion favors
comparator
.
4 Study drug becomes non-signiﬁcant .
Comparisons (n=11) where Composite is signiﬁcant and LOCF is
1 (a) Study drug gains superiority on efﬁcacy primary .
1 (b) Study drug gains superiority on efﬁcacy secondary .
2 Study drug gains superiority on primary efﬁcacy
measure
.
3 Study drug gains superiority on primary efﬁcacy
measure
.
4 (a) Study drug gains superiority on secondary efﬁcacy
measure
.
4 (b) Study drug gains superiority on secondary efﬁcacy
measure
.
4 (c) Study drug gains superiority on secondary efﬁcacy
measure
.
4 (d) Study drug gains superiority on secondary efﬁcacy
measure
.
5 Differentiates dosing arms of study treatment .
6 Reverses ﬁndings in favor of active comparator .
7 Reverses ﬁndings in favor of active comparator .
nComposite approach: Formula used for combining p values p=p(d
of difference in drop out and p(e) is the one tailed p value of differ
nnAssumed not signiﬁcant since p values are not combined if th
completion but less improvement than drug b. Under such a conditio
null hypothesis is not rejected, thus it is assumed to have a p valueand efﬁcacy were higher in the same study treatment arm).
However z-scores were combined under all conditions. Analyses
were run using SPSS (version 18.0.1).3. Results
3.1. Active controlled trials
3.1.1. Comparisons of study drug and active control
treatments
Table 1 presents the difference between study arms obtained in
effect sizes using various approaches. They are presented from
ﬁrst to last column: yes/no completion, completers change
from baseline to endpoint ANCOVA, composite approach – which
combines the previous two tests, LOCF ANCOVA analysis, mixed
models and the difference between the composite approach
and LOCF ANCOVA and mixed models. The composite approach
detected more difference in effect size than LOCF (ES=.05)
and MMRM (ES=.08).
Table 2 compares composite p value with LOCF (ANCOVA)
and Mixed Effects Models. In 65.3% (n=32/49) of compar-
isons within studies, the composite p value was lower thanApproach give different results.
ompletion
=
ANCOVA
completers p=
ANCOVA_ALL
p=
Composite
p= *
ot
23 .59 .02 Not
signiﬁcant**
68 .06 .03 Not
signiﬁcant**
60 .00 .00 Not
signiﬁcant**
05 .80 .03 .054
not
06 .41 .10 .04
34 .06 .17 .03
08 .13 .28 .02
04 .01 .53 .00
01 .75 .06 .01
05 .61 .21 .04
01 .69 .29 .01
02 .61 .18 .02
08 .46 .07 .05
06 .62 .06 .05
00 .33 .15 .00
)p(e) (1 ln(p(d)p(e)) where p(d) is the p one tailed value
ence in completers analysis of efﬁcacy
e tests go in opposite directions. That is if drug a has higher
n a difference cannot be established using this method and the
of 4.05.
J. Rabinowitz et al.362LOCF p value, which in 10 cases was signiﬁcant (pr.05)
where LOCF was not, and in 3 LOCF was signiﬁcant and
composite was not. In the 29 remaining comparisons there
were no differences in meeting statistical signiﬁcance
(pZ.05) (Tables 2 and 3).
3.1.2. Comparisons of different dose arms of same
active treatment
In 89.8% (n=44/49) of the comparisons, the composite p
value was lower than MMRM p value, which in 10 cases was
signiﬁcant where MMRM was not, and in 2 MMRM was
signiﬁcant and composite was not. In the 30 remaining
comparisons there were no differences in meeting signiﬁ-
cance (Tables 2–4). The composite approach detected less
difference in effect size (ES=.07) than LOCF and MMRM
(ES=.05) (Table 1). In 52.4% (n=11/21) of comparisons the
composite p value was lower than LOCF p value, which in no
cases was signiﬁcant where LOCF was not, and in 1 LOCF
was signiﬁcant and composite was not. In the 20 remainingTable 4 Active treatment studies where MMRM and Composite
Study Comparisons of study drug and active comparator
arms
Com
Comparisons (n=4) where MMRM is signiﬁcant and Composite is
201 Difference between dosing arms on study drugs
becomes signiﬁcant
.60
201 Difference between dosing arms on study drugs
becomes signiﬁcant
.68
307 Study drug becomes signiﬁcant (PANSS is secondary
efﬁcacy measures)
.87
com
308 Study drug becomes signiﬁcant (PANSS is secondary
efﬁcacy measure)
.05
Comparisons (n=10) where composite is signiﬁcant and MMRM i
201 Study drug gains superiority on efﬁcacy primary .06
201 Study drug gains superiority on efﬁcacy secondary .34
304 Study drug gains superiority on primary efﬁcacy
measure
.07
306 Study drug gains superiority on primary efﬁcacy
measure
.04
307 Study drug gains superiority on secondary efﬁcacy
measure
.88
310 Study drug gains superiority on secondary efﬁcacy
measure
.05
310 Study drug gains superiority on secondary efﬁcacy
measure
.01
310 Study drug gains superiority on secondary efﬁcacy
measure
.02
518 Reverses ﬁndings on secondary efﬁcacy measure in
favor of active comparator
.06
519 Reverses ﬁndings in favor of active comparator on
secondary efﬁcacy measure
.00
nComposite approach: Formula used for combining p values p=p(d)
of difference in drop out and p(e) is the one tailed p value of differ
nnAssumed not signiﬁcant since p values are not combined if th
completion but less improvement than drug b. Under such a conditio
null hypothesis is not rejected, thus it is assumed to have a p valuecomparisons there were no differences in meeting statisti-
cal signiﬁcance (Tables 2 and 3). In 85.7% (n=18/21) of
comparisons, the composite p value was lower than MMRM
p, which in no cases was signiﬁcant where LOCF was not,
and in 2 MMRM was signiﬁcant and composite was not. In the
19 remaining comparisons there were no differences in
meeting signiﬁcance (Tables 2 and 3).3.2. Placebo controlled trials
3.2.1. Active comparisons in placebo controlled studies
The composite approach detected more difference in effect
size between SGA and FGA than LOCF (ES=.10) and
between different doses of active treatment ES=.04; SGA
vs. control SGA; (ES=.02) and MMRM (SGA vs. FGA, ES=.06;
different doses of active treatment ES=.01; SGA vs. control
SGA ES=.01) (Table 1). In 40% (n=11/31) of comparisons
between SGA and FGA active treatments, the composite pApproach give different results.
pletion p= ANCOVA
completers p=
MMRM
ALL p=
Composite
p=n
not
.12 .04 Not
computednn
.06 .02 Not
computednn
(favoring active
parator)
.05 .01 Not
computednn
.79 .03 .05
s not
.41 .23 .04
.06 .13 .03
.12 .60 .001
.01 .60 .001
.004 .50 .01
.61 .36 .04
.69 .14 .01
.61 .16 .02
.62 .18 .05
4 .33 .17 .003
p(e) (1 ln( p(d)p(e)) where p(d) is the p one tailed value
ence in completers analysis of efﬁcacy
e tests go in opposite directions. That is if drug a has higher
n a difference cannot be established using this method and the
of 4.05.
Table 5 Placebo controlled studies where LOCF and Composite Approach give different results comparing study drug to placebo or active control.
NewMeds
Study no
Comparison: P – placebo, FG – ﬁrst generation antipsychotic,
SG – Second generation antipsychotic,
SGA-C – Second generation antipsychotic as active control
Arm superior on
dropout and
completers efﬁcacy
ANCOVA
LOCF
Completion
p value of
Chi-Square
Completers
analysis, p value
of ANCOVA
Composite p
(Completion p and
Completers ANCOVA)
105 5 doses SG–P–FG
SG vs. P: 3 comparisons both signiﬁcant; 1 neither signiﬁcant;
1 LOCF sig composite not; SG vs. FG: 4 neither signiﬁcant;
1 LOCF signiﬁcant but not composite
P-FG .01 .76 .04
P vs. SG dose a SG .02 .58 .06 .05
P vs. SG dose b SG .033 .29 .33 .11
FG vs. SG dose c .05 .82 .09 .
202 4 doses SG–P–FG .
SG dose a,b,c,d vs. P: LOCF and composite signiﬁcant
SG vs. FG 1 signiﬁcant on both; 2 signiﬁcant on neither.
1 signiﬁcant only on LOCF.
FG vs. P: Both signiﬁcant
FG vs. SG dose c .01 .01 .93
203 SG–P–FG
SG vs. P both signiﬁcant.
FG vs. P LOCF signiﬁcant composite not.
FG vs. SG neither signiﬁcant.
Placebo–FG FG .01 .29 .87 .24
204 SG 2 doses–P
SG dose b vs. P 1 both signiﬁcant, dose a LOCF but not composite
SG dose a vs. P SG .04 .92 .09 .10
212 SG–P–SGC
– SG vs. P both signiﬁcant.
– SG-C vs. P composite signiﬁcant LOCF not.
– SG-C vs. SG neither signiﬁcant.
SGC vs. P SG-C .12 .05 .05 .01
217 3 doses vs. SGC vs. P
SG, SG-C vs. P. all signiﬁcant on both.
SG-C vs. SG dose a not signiﬁcant on LOCF, composite
SG-C signiﬁcantly better.
SG-C vs. SG dose a SG-C .30 .02 .53 .02
SG dose a vs. dose c SG dose C .07 .01 .42 .004
218 SG–SG-C–P
SG vs. P signiﬁcant on both. SG-C vs. P not signiﬁcant on either.
SG vs. SG-C signiﬁcant on composite not on LOCF.
SG vs. SG SG .13 .08 .35 .04
301 SG 3 doses–FGC vs. P .
SG vs. P dose c signiﬁcant on both. FGC vs. P signiﬁcant on LOCF, but not composite.
SG vs. FG-C dose a signiﬁcant LOCF but not composite. Dose b not signiﬁcant on
either. Dose c signiﬁcant on composite but not LOCF.
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Table 5 (continued )
NewMeds
Study no
Comparison: P – placebo, FG – ﬁrst generation antipsychotic,
SG – Second generation antipsychotic,
SGA-C – Second generation antipsychotic as active control
Arm superior on
dropout and
completers efﬁcacy
ANCOVA
LOCF
Completion
p value of
Chi-Square
Completers
analysis, p value
of ANCOVA
Composite p
(Completion p and
Completers ANCOVA)
FGC vs. P .001 .00 .26
SG dose b vs. P .002 .47 .99 .
FGC vs. SG dose a SG .05 .17 .63 .12
FGC–SG dose c SG .28 .001 .12 .00
402 SG 3 doses-P
SG dose a, b vs. P not signiﬁcant on either. Dose c signiﬁcant on LOCF.
P-SG dose c .02 .98 .06
403 SG 2 doses-SGA-C vs. P
SG dose a vs. P signiﬁcant LOCF but not composite. SG dose b vs. P signiﬁcant on
both. SGA-C dose a and b vs. SG neither signiﬁcant.
P vs. SG dose c SG dose c .05 .83 .26 .21
404 SG 2 doses-FG–P
SG dose a, b vs. P both not signiﬁcant. FG vs. P signiﬁcant on LOCF but not
composite. SG dose a, b vs. FG not signiﬁcant on either.
.
P–FG .02 .09 .51
405 SG 3 doses–FGC 3 doses vs. P
All SG vs. SGC not signiﬁcant on either.
P vs. FGC: signiﬁcant on LOCF but not composite
P vs. SG: dose c signiﬁcant on both, P vs. SG dose a and b signiﬁcant on LOCF but
not composite.
FGC dose b vs. P FG dose b .00 .87 .19 .17
FGC dose a vs. P .003 .61 .49 .
FGC dose c vs. P .02 .67 .75 .
SG dose b vs. P .03 .58 .33
SG dose c vs. P .03 .80 .06
510n SG 3 doses-P
SG vs. P: Composite signiﬁcant all, LOCF not.
P vs. SG SG .12 .001 .35 .001
P vs. SG SG .31 .001 .62 .002
P vs. SG S .15 .00 .76 .00
512n SG 2 doses–P
SG vs. P: Both doses signiﬁcant on composite but not LOCF.
P vs. SG SG .13 .01 .07 .001
P vs. SG SG .81 .02 .12 .01
nStudy failing to show signiﬁcance of active treatment over placebo.
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365Combining efﬁcacy and completion rates with no data imputationvalue was lower than LOCF p value, which in no cases was
signiﬁcant (pr.05) where LOCF was not, and in 6 LOCF was
signiﬁcant and composite was not. In the 25 remaining
comparisons there were no differences in meeting statistical
signiﬁcance (pr.05) (Tables 2 and 3). In 33.3% (n=20/60)
of comparisons between different active treatments, the
composite p value was lower than MMRM p value, which in
7 cases was signiﬁcant (pr.05) where MMRM was not, and in
6 comparisons MMRM was signiﬁcant and composite was not.
In the 47 remaining comparisons there were no differences in
meeting statistical signiﬁcance (p=.05) (Tables 2–4).
In comparing the different dose arms of the same active
drug, the composite p value was lower than LOCF in 40.0%
(n=24/60) of comparisons, which in 6 cases was signiﬁcant
where LOCF was not, and in 5 LOCF was signiﬁcant and
composite was not. In the 49 remaining comparisons there
were no differences in meeting signiﬁcance (Tables 2–4). In
33.3% (n=20/60) the composite p value was lower than
MMRM p value, which in 7 cases was signiﬁcant where MMRM
was not, and in 6 MMRM was signiﬁcant and composite was
not. In the 47 remaining comparisons there were no
differences in meeting statistical signiﬁcance (Tables 2–4).
In comparing between control SGA and study drug SGA, the
composite p value was lower than LOCF in 55.6% (n=5/9) of
comparisons, the composite p value was lower than MMRM p
value, which in 7 cases was signiﬁcant where MMRM was not,
and in 6 MMRM was signiﬁcant and composite was not. In theTable 6 Placebo controlled studies where MMRM and Compos
placebo or active control.
NewMeds Study no. Comparison Completio
MMRM sig composite not
102 Placebo vs. study drug .24
105 Control vs. study drug .76
204 Placebo vs. study drug .66
301 Placebo vs. study drug .43
301 Placebo vs. study drug .30
301 Placebo vs. study drug .43
403 Placebo vs. study drug .83
405 Placebo vs. active control .87
Composite sig MMRM not
105 Placebo vs. study drug .41
105 Placebo vs. study drug .09
203 Placebo vs. study drug .10
210 Placebo vs. study drug .01
210 Placebo vs. study drug .01
212 Placebo vs. study drug .08
214 Placebo vs. study drug .03
217 Placebo vs. study drug .03
218 Placebo vs. study drug .24
218 Placebo vs. study drug .08
508 Placebo vs. study drug .02
510 Placebo vs. study drug .001
512 Placebo vs. study drug .01
512 Placebo vs. study drug .02
nComposite approach: Formula used for combining p values p=p(d
of difference in drop out and p(e) is the one tailed p value of differ47 remaining comparisons there were no differences in
meeting signiﬁcance (Tables 2–4).3.2.2. Placebo vs. active control treatment
comparisons
There was almost no difference in effect size between the
composite approach and LOCF (ES=.01) (Table 1). In 18 of
73 comparisons (24.6%) composite p value was lower than
LOCF. In 4 comparisons composite approach was signiﬁcant
when LOCF was not (planned analyses in these studies
differed somewhat and were signiﬁcant in these trials),
which would have saved two trials from failure; in 8 com-
parisons LOCF was signiﬁcant where composite was not (this
would not have changed the status of a trial); in 40 they
were both signiﬁcant; and in 21 neither was signiﬁcant
(Tables 2, 5 and 6).
The relatively poor sensitivity of the composite approach
in the placebo active comparisons in the placebo controlled
trials is due to the considerably smaller effect size of active
treatment vs. placebo differences among completers than
among all cases as captured by LOCF (.24 vs. .35). The
superiority of active treatment on completion rates was not
sufﬁcient to compensate for this. In all studies, at least one
active treatment arm had higher completion rates than
placebo. In 21 of 29 studies all active treatment arms had
higher completion rates than the placebo arms; in 9 of theseite Approach give different results comparing study drug to
n p ANCOVA p (completers) Mixed models p Composite pn
.18 .01 .06
.09 .04 .08
.09 .02 .08
.26 .02 .13
.89 .001 .25
.99 .01 .34
.26 .04 .21
.19 .01 .17
.03 .09 .02
.33 .19 .04
.28 .09 .04
.10 .06 .002
.91 .37 .01
.05 .06 .01
.31 .35 .02
.53 .25 .02
.05 .07 .02
.35 .22 .04
.29 .06 .01
.76 .20 .002
.07 .13 .001
.12 .81 .01
)p(e) (1 ln(p(d)p(e)) where p(d) is the p one tailed value
ence in completers analysis of efﬁcacy
J. Rabinowitz et al.366studies these differences were statistically signiﬁcant for all
arms and in 16 studies at least one study arm comparison
was statistically signiﬁcant. Of the 73 placebo active
treatment comparisons, completion rates were signiﬁcantly
better in 22 cases at po.01 and in 32 cases at po.05.4. Discussion
The composite approach was more sensitive to change, as
reﬂected by larger effect sizes, than LOCF and MMRM in
active treatment comparator studies and when comparing
active arms in placebo controlled studies. We argue that the
composite approach answers a conceptually and clinically
more relevant question by simultaneously considering dif-
ferences in dropout and differences in efﬁcacy. The lack of
increased sensitivity of the composite approach in the
placebo controlled studies is probably due to the anomaly
that many placebo patients probably stop prematurely due
to poor efﬁcacy, thus those who remain in the trial are doing
unusually well. This calls into question the utility of the
composite approach for placebo controlled trials and points
to a logical ﬂaw in the approach for such studies, since
patients who complete on placebo are not representative of
persons needing treatment.
The composite approach provides a single test that com-
bines two separate p values. Aside from the theoretical
rationale of applying this approach, combining p values can
result in overall level of signiﬁcance being less than .05 where
neither or only one of the tests reaches that level. Table 7
shows combinations of p values that render combined p values
statistically signiﬁcant at po.05. For example, if one p value
is .01, then the second one can be as high as .80 and the
results can still be signiﬁcant, if both p values are .09 or lower,
the overall test will be statistically signiﬁcant.
The composite approach appears to be more sensitive to
treatment arm differences in active treatment comparisons
both in active controlled and placebo controlled trials. An
improvement of .05 in the detected effect size difference
would greatly reduce the number of patients needed while
preserving study power. For example, an expected effect
size difference of .30 in a two arm trial, with a two-sided
p-value .05 at 85% power, would require 201 patients per
arm, and the same with an expected difference of .35 would
only require 148 patients per arm, a reduction of 53
patients per arm. The same difference from .25 to .30Table 7 Combinations of p values (equal to or less
than) that render po.05 (p=.047).
p1 p2
.01 .8
.02 .4
.03 .27
.04 .2
.05 .17
.06 .14
.07 .12
.08 .10
.09 .09would result in a savings of 88 patients per arm; and from
.25 to .20, 161 patients per arm.
While there are no formally established procedures for
conducting a power analysis of the composite approach, and
more work is needed in this area, we offer the following:
when planning sample size for a study that will use the
composite approach, consideration should be given to the
expected dropout rate, expected difference in dropout rate
and the expected difference in the completers analysis.
The power of the completers analysis is contingent upon the
dropout rate. So whereas the ﬁrst p value, yes/no comple-
tion, will be available for all cases, the completers analysis
will be reduced by dropout. Thus the dropout rate reduces
statistical power for the second p value and hence the
combined p value. In the following example we assume that
the expected dropout rate for the ﬁrst treatment is 20% and
for the second 35%, thus an odds ratio of 2.15, and the
expected difference on effect size on efﬁcacy among
completers was at least .30. We are assuming that each of
the two p values will contribute equally, so that each test
would need to be po.09. For the ﬁrst test, OR=2.15, to
have 90% power, we would need 134 patients per arm and
for the second, ES=.30, we would need 154 per arm.
However based on the dropout rate (27%) we would
expect that of the 134 patients per arm needed for the
ﬁrst test 111 would remain for the second test, which would
give 81% power, thus the overall power would be below 90%.
To ensure 90% power would require increasing the sample
size. If the sample size were set at 160 patients per arm for
the ﬁrst test it would have 94% power and the second would
have 86% power (n=133 per arm).
In addition to providing a more sensitive method to
test differences between active treatments, the composite
approach, we believe, answers conceptually a more relevant
question. LOCF and MMRM answer the question what would
the differences be if all persons completed the trial. As noted
by Shih and Quan (Shih and Quan, 1997), the composite
approach answers a more clinically important question as
could be expressed by a physician to a patient: You need to
take this hypertension medication for 6 months as prescribed.
If you complete the 6 month course of treatment, I expect
your blood pressure will be lowered by 15%. But, according to
the clinical trials, there is 10% chance that you may not
complete the prescribed course for a variety of reasons in
which case the medicine will be of little use to you. The
composite approach thus combines this information into a
single, more clinically meaningful test.
Shih and Quan have noted that while the two statistics for
the two individual hypotheses (p1, completion and p2,
improvement among completers) are dependent, the asso-
ciated p-values are stochastically independent (Shih and
Quan, 1997; Shih and Quan, 2001). They explain that this is
because we know that p2, for any ﬁxed number of dropouts,
is uniformly distributed in [0, 1] under the null hypothesis.
Thus it is stochastically independent of the value assumed
by number of dropouts. In addition, p1 is uniquely deter-
mined by dropout, so that p2 is not only stochastically
independent of drop out, but also of p1. To err on the side of
caution we empirically examined in our repository the
correlation of the two measures, dropout and completers.
We aggregated the placebo and treatment arms in each
study and computed the mean completion rate and the
367Combining efﬁcacy and completion rates with no data imputationmean change to planned study endpoint. Completion by
planned last visit change in placebo controlled studies
(partial correlations controlling for baseline) was r=.26
(n=29), p=.18 and for active controlled treatment was
r=.12 (n=30), p=.56. If we assume that the two tests that
we have combined are dependent, and not as suggested by
Shih and Quan, then we can apply a correction for dependence
as expressed by the correlation. A suitable correction is 1/
(SQRT(1+(n1) r)), where n is the number of p values per
study being combined (2 in the case of the composite
approach as applied in this paper) and r is the correlation
(Strube, 1985). Thus for the active treatment studies the
adjusted combined p value would be 94% of the unadjusted
and for placebo controlled studies 89%. It is arguable if this
adjustment is needed, but even if it were, it would have little
effect on the results. We note also that there are other
methods of adding p-values but these generally give similar
results (Rabinowitz and Davidov, 2008).
Our current analysis assumes that the higher sensitivity
obtained by using the composite approach is due to, a
better ability to discern a true difference that exists, and
not a spurious inﬂation of effect size. We base this assump-
tion on the conceptual argument that combining these two
clinically relevant pieces of information increases a trial's
clinical meaningfulness. Expected differences were not
found in placebo active comparisons and the composite
approach may introduce bias when used in these compar-
isons as patients who complete a trial on placebo are not a
clinically meaningful comparison.
We chose for comparison LOCF and MMRM which have
both been used in previous trials. As noted by Hamer and
Simpson (2009) LOCF does not answer a particularly useful
or interesting clinical question: “Regardless of how long the
drug is taken, and of the proportion of the subjects in the
study who discontinued, or when or why they discontinued,
are the ﬁnal scores on some clinical rating scale lower in
subjects taking one drug compared with another?” When the
number of subjects is sufﬁciently large and missing data is
sparse, then mixed models are preferable to LOCF. However
if either of those conditions does not hold, or when the data
are not missing for a particular reason related to the study,
neither methods work particularly well (2009).
We recognize that regulators have traditionally accepted
the LOCF approach in all intention-to-treat patients, and
are increasingly accepting the MMRM analyses, perhaps
ignoring the underlying assumptions made about missing
data. The regulators often tend to be conservative and may
hesitate in accepting this composite approach as it com-
bines two elements of outcome. However it can be argued
that this composite is both statistically more robust, as it
does not make assumptions about missing data and more
clinically meaningful in active treatment comparator stu-
dies than either MMRM or LOCF on the primary endpoint
alone. When applying the composite approach we recom-
mend not only reporting the combined p values, but also the
individual test values even if the combined p value is the
protocol deﬁned test.
Early adoption of this approach for smaller Phase II active
comparator studies that may be under-powered on the
primary endpoint alone may be recommended. Prospectively
applying the composite statistic would provide greater
assurance to the evaluators that there is greater likelihoodof a true effect in subsequent trials with larger sizes. There is
an increasing recognition that multiple approaches are
appropriate in analyzing clinical trial data and that extensive
sensitivity analysis should be conducted using approaches
that make various assumptions about missing data (Guideline
on Missing Data in Conﬁrmatory Clinical Trials, 2010; Panel on
Handling Missing Data in Clinical Trials, 2010). The current
results support including the composite approach in the
armamentarium of approaches for active-controlled
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